African News

Preventing the spread of the Ebola Virus Disease (EVD) in West Africa

28 September 2014 at 09:17 | 3089 views

Analysis

By Nanah Sheriff-Fofanah Sesay, MSN, RN, FNP-BC, USA.

Ebola is an infectious and generally fatal disease marked by fever and severe internal bleeding, spread through contact with infected body fluids by a virus whose normal host species is unknown. This disease was originally identified in 1976 in the Democratic Republic of Congo (formerly Zaire), as such the disease was named after a river in the Democratic Republic of Congo.

The genus Ebola is divided into five different species (the Zaire, Sudan, Ivory Coast, Bundibugyo, and Reston agent), these viruses differs in their virulence for human (Bray, Hirsch, & Mitty, 2014). The Ebola virus enters the body through mucous membrane, breaks in the skin, or parenterally. The virus then infect multiple cell types, that normally provides immunity including: monocytes, macrophages, dendritic cells, endothelial cells, fibroblasts, hepatocytes, adrenal cortical cells, and epithelial (CDC, 2014).

Whatever the point of entry into the body is, the Ebola virus initially infect macrophages and dendritic cells markedly decreasing the host ability to fight infections. The virus then rapidly replicate infecting multiple organs such as the liver, lung, heart, kidneys, intestines etc., causing their necrosis and releasing a large number of new viral particles into extracellular fluids, further spreading into the lymph nodes, followed by the dendritic cells (Bray, Hirsch, & Mitty, 2014).

This rapid systemic response is enhanced by virus-induced suppression of type 1 interferon responses. Failure of adoptive immunity through impaired dendritic cells function and lymphocytes apoptosis helps to explain how this virus is able to cause severe, frequent fatal illness (Bray, Hirsch, & Mitty, 2014). The coagulation defects is seen when the Ebola virus infected macrophages produce cell surface tissue factor (TF), triggering the extrinsic coagulation pathway and thus the hemorrhagic effect of EVD.

People infected by the EVD initially present with non-specific influenza-like symptoms such as muscle ache, fatigue, chills, and fever. These symptoms can progress to multi-organ failure and septic shock. Other signs and symptoms includes but not limited to: generalized muscle weakness, poor appetite, severe headache, low pulse rate (bradycardia), high fever, dry cough, sore throat with swollen lymph nodes, rash involving the face, neck, trunk, and arms by day five to seven of the illness, abdominal pains associated with nausea, vomiting, and watery diarrhea, bleeding associated with petechial, ecchymosis, bruising, oozing from venipuncture sites, mucosal hemorrhage, and sometimes frank hemorrhage.

Other symptoms of the EVD infection includes: hiccups, chest pain, shortness of breath, confusion, seizures, cerebral edema, conjunctival injection, dark red discoloration of the soft palate, and pregnant women may experience spontaneous miscarriage (Bray, Hirsch, & Mitty, 2014).

The incubation period for the EVD is between 8 to 10 days after exposure to the Ebola virus but may range between 2 to 21 days. According to Bray, Hirsch, and Mitty (2014), follow up studies of approximately 40 survivors in the 1995 KiKwit, Democratic Republic of Congo outbreak showed that viral RNA sequences could be detected by RT-PCR in the semen of male patients for up to 3 months.

The latest and largest outbreak of EVD is currently taking place in Guinea, Liberia, Sierra Leone, Nigeria, and Senegal. As of September 21, 2014, the World Health Organization (WHO) reported a total case count of 6,263 people infected with the EVD, and 2,917 deaths with statistics as follows:

- Guinea: total case count of 1,022, total deaths of 635, and laboratory confirmed cases of 890 (CDC, 2014).

- Liberia: total case count of 3,280, total deaths of 1,677, and laboratory confirmed cases of 890 (CDC, 2014).

- Nigeria: total case count of 20, total deaths of 8, and laboratory confirmed cases of 19 (CDC, 2014).

- Senegal: total case count of 1, total case death of 0, and laboratory confirmed case of 1 (CDC, 2014).

- Sierra Leone: total case count of 1,940, total case deaths of 597, and laboratory confirmed cases of 1,745 (CDC, 2014).

Even though the focus of this article is on prevention of EVD, the readers may not appreciate the significance of prevention without having a first hand knowledge about the virus, its pathogenesis, signs and symptoms, incubation period, and current statistics in West Africa.

In order to achieve tight control of this sentinel disease, key stakeholders must heavily invest into the mode of transmission other than what is already known. In the article titled Ebola, Aids, Manufactured by Western Pharmaceuticals, US Department of Defense (DoD), Dr. Cyril Broderick wrote about the WHO, and United Nations agencies’ participation in research studies involving infectious diseases such as Ebola in West Africa. There are also reports of the existence of Ebola and other infectious disease infected monkeys in Liberia. In order to break the chain of transmission of the EVD, these implications cannot and should not be ignored by any means.

At present, the spread of EVD is prevented by washing hands frequently with soap, water, alcohol based hand rub, chlorine, avoiding the ingestion of wild animals such as bush meat, monkeys, bats etc., non-contact with infected person’s body fluids such as sweat, emesis, sputum, blood, semen, vaginal secretions, saliva, and feces.

Other prevention methods include wearing protective clothing such as gloves, masks, gowns, and eye shields otherwise known as personal protective equipment (PPE). People in close proximity of potential EVD infected individuals should contact the appropriate authorities immediately and health workers who are charged with the responsibilities of handling the remains of EVD infected individuals must be specially organized and trained to bury the remains using PPEs as these bodies are still contagious (Mayo Clinic, 2014). Lastly, individuals who are exposed to the EVD must be placed on contact isolation until their EVD negative status is confirmed.

Based on evidence-based literature on the prevention of the EVD in affected countries in West Africa, appropriate preventive modalities are being implemented to deter the spread of the disease yet total case counts, deaths, and laboratory confirmed cases continue to escalate. It is therefore my recommendation that key stakeholders re-evaluate the current prevention modalities and invest heavily on all possible causes of EVD.

Comments